Accuro Epidural Guiding Device Demonstrated Superior for

0

CHARLOTTESVILLE, Va., Aug. 16, 2022 (GLOBE NEWSWIRE) — RIVANNA®, developer of first imaging-based medical solutions, announced the results of a clinical case study demonstrating that Accuro has played a crucial role in the assistance with the placement of an epidural catheter in a parturient suffering from extreme obesity. The study, published in The Ultrasound Diaryfurther concluded that the benefits achieved by pre-procedural AI-US are manifold:

• increases patient satisfaction,

• allows immediate recognition of anatomical structures,

• increases success rates on the first attempt,

• reduces needle placement times,

• and predicts the direction and distance of the needle from the skin to reach target structures.

As reported in the study, a patient requesting epidural analgesia for labor presented with a calculated BMI of 64.5 kg. Initial landmark palpation for localization of the interspinous spaces was unsuccessful. Second, acquiring standard ultrasound imaging of the lumbar spine was ineffective in identifying target structures due to the amount of subcutaneous tissue. Accuro, which uses AI-enabled automatic spine anatomy recognition, provided quick identification of the desired disc space, correct point for needle insertion and estimated depth of the epidural space. A senior attending physician placed the epidural catheter the first time.

Quoting the study, “…morphological alterations secondary to pregnancy and obesity created difficulties that could not be overcome using traditional landmark palpation nor standard ultrasound techniques.”

“Numerous studies have confirmed the efficacy and safety of the Accuro-guided technique over the palpation-based approach for spinal placement or epidural catheterization,” commented Will Mauldin, Ph.D. ., co-founder and CEO of RIVANNA. “This study is notable for examining the viability of standard ultrasound imaging during labor and delivery, particularly in obese patients, as the visibility of the ligamentum flavum, dura and space epidural decreases significantly during pregnancy.”

Proficiency in neuraxial ultrasound using conventional equipment relies on the operator to provide accurate results. Conversely, Accuro’s integrated AI-US technology provides clinicians with more detailed information that can be crucial in complex clinical scenarios. It may offer a new advantage in improving results and training operators inexperienced in neuraxial ultrasound techniques.

Conducted by the Division of Anesthesiology, Critical Care and Pain Medicine at the University of Parma, Parma, Italy, the clinical case study was published in The Ultrasound Diary volume 14, article number: 34 (2022).

ABOUT RIVANNA

RIVANNA® is a commercial-stage medical device innovator and manufacturer in Charlottesville, Virginia. RIVANNA’s mission is to develop and commercialize the first imaging-based medical technologies that elevate global standards of care. RIVANNA’s technology platform combines the advantages of ultrasound with the bone imaging capabilities of X-rays to address unmet clinical needs. BoneVision™ and BoneEnhance® optimize ultrasound image acquisition and visualization to provide radiation-free alternatives to X-ray imaging. When combined with SpineNav3D™ AI-enabled image recognition, the platform offers comprehensive clinician support that improves decision-making, clinician workflows, health outcomes and patient satisfaction. The company operates an FDA registered and ISO 13485:2016 certified manufacturing facility where it produces the Accuro® product line and associated medical equipment and components. For more information, visit rivannamedical.com.

Media contact: [email protected]

This content was posted through the press release distribution service on Newswire.com.

Share.

About Author

Comments are closed.